Evidence map›Paper›PMID 20716359›Full record

ArticleRetrovirology2010

Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies.

Xiaoxing Qiu, Priscilla Swanson, Ka-Cheung Luk, Bailin Tu, Francois Villinger, Jaydip Das Gupta, Robert H Silverman, Eric A Klein, Sushil Devare, Gerald Schochetman and 1 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Retrovirology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Recombinant origin of the retrovirus XMRV.Science (New York, N.Y.) · 2011
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Xiaoxing QiuInfectious Diseases R&D, Abbott Diagnostics, 100 Abbott Park Rd, Abbott Park, IL 60064, USA. xiaoxing.qiu@abbott.com
Priscilla Swanson
Ka-Cheung Luk
Bailin Tu
Francois Villinger
Jaydip Das Gupta
Robert H Silverman
Eric A Klein
Sushil Devare
Gerald Schochetman
John Hackett
Abbott Fund · USCleveland Clinic · USEmory University · US

Funding

Role of RNase L in the Biology of Prostate CancerR01CA103943 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI SILVERMAN, ROBERT H. · 2004 to 2008
$1.5M
NCI NIH HHS CA103943PHS HHS DRR000165
6 · The paper itself

Abstract

backgroundXenotropic Murine Leukemia Virus-related Virus (XMRV) is a human gammaretrovirus recently identified in prostate cancer tissue and in lymphocytes of patients with chronic fatigue syndrome. To establish the etiologic role of XMRV infection in human disease requires large scale epidemiologic studies. Development of assays to detect XMRV-specific antibodies would greatly facilitate such studies. However, the nature and kinetics of the antibody response to XMRV infection have yet to be determined.

resultsThree rhesus macaques were infected with XMRV to determine the dynamics of the antibody responses elicited by infection with XMRV. All macaques developed antibodies to XMRV during the second week of infection, and the predominant responses were to the envelope protein gp70, transmembrane protein p15E, and capsid protein p30. In general, antibody responses to gp70 and p15E appeared early with higher titers than to p30, especially in the early period of seroconversion. Antibodies to gp70, p15E and p30 persisted to 158 days and were substantially boosted by re-infection, thus, were identified as useful serologic markers. Three high-throughput prototype assays were developed using recombinant proteins to detect antibodies to these viral proteins. Both gp70 and p15E prototype assays demonstrated 100% sensitivity by detecting all Western blot (WB) positive serial bleeds from the XMRV-infected macaques and good specificity (99.5-99.9%) with blood donors. Seroconversion sensitivity and specificity of the p30 prototype assay were 92% and 99.4% respectively.

conclusionsThis study provides the first demonstration of seroconversion patterns elicited by XMRV infection. The nature and kinetics of antibody responses to XMRV in primates were fully characterized. Moreover, key serologic markers useful for detection of XMRV infection were identified. Three prototype immunoassays were developed to detect XMRV-specific antibodies. These assays demonstrated good sensitivity and specificity; thus, they will facilitate large scale epidemiologic studies of XMRV infection in humans.

Indexed as

AnimalsAntibodies, ViralDisease Models, AnimalEpidemiologic StudiesFemaleGammaretrovirusHumansImmunoassayMacaca mulattaMaleRecombinant ProteinsRetroviridae InfectionsSensitivity and SpecificityViral Structural ProteinsVirologyAntibodies, ViralRecombinant ProteinsViral Structural Proteins

Identifiers

PMID20716359
PMCPMC2931451
OpenAlexW2115596900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.